tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morrissey PE | Prope tolerance: is it the end or the means? | 2009 | Transplantation | pmid:19502973 |
| Egawa H et al. | FK506 conversion therapy in pediatric liver transplantation. | 1994 | Transplantation | pmid:7513911 |
| Moss MC et al. | Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? | 2014 | Transplantation | pmid:24492429 |
| Yang CW et al. | Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. | 2001 | Transplantation | pmid:11740384 |
| Narayanan M et al. | Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. | 2013 | Transplantation | pmid:23423268 |
| Moxey-Mims MM | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1999 | Transplantation | pmid:10440413 |
| Firdaous I et al. | Pediatric intravenous FK506--how much are we really infusing? | 1994 | Transplantation | pmid:7517079 |
| Donnadieu B et al. | Central retinal vein occlusion-associated tacrolimus after liver transplantation. | 2014 | Transplantation | pmid:25955343 |
| Soccal PM et al. | Improvement of drug-induced chronic renal failure in lung transplantation. | 1999 | Transplantation | pmid:10428288 |
| Lee CM et al. | Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. | 1997 | Transplantation | pmid:9371670 |
| Dhar DK et al. | Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. | 1993 | Transplantation | pmid:7506456 |
| Yates CJ et al. | Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. | 2013 | Transplantation | pmid:23902993 |
| Sharif A et al. | Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. | 2010 | Transplantation | pmid:20145524 |
| Moutabarrik A et al. | FK506-induced kidney tubular cell injury. | 1992 | Transplantation | pmid:1281562 |
| Uemura T et al. | Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. | 2011 | Transplantation | pmid:21841541 |
| Ho ET et al. | Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. | 2013 | Transplantation | pmid:23542469 |
| Aw MM et al. | Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. | 2001 | Transplantation | pmid:11544444 |
| Fujii Y et al. | Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. | 1989 | Transplantation | pmid:2472025 |
| Terakura M et al. | Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. | 1998 | Transplantation | pmid:9721804 |
| Veroux M et al. | Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. | 2012 | Transplantation | pmid:22298033 |
| Kai N et al. | Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. | 1993 | Transplantation | pmid:7682740 |
| Chapman WC et al. | Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation. | 2017 | Transplantation | pmid:28121741 |
| Jacobson PA et al. | Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. | 2011 | Transplantation | pmid:21206424 |
| Nolan TJ and Schad GA | Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. | 1996 | Transplantation | pmid:8878405 |
| Klupp J et al. | Indications of mycophenolate mofetil in liver transplantation. | 2005 | Transplantation | pmid:16286893 |
| Opelz G and Döhler B | Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. | 2009 | Transplantation | pmid:19300179 |
| Rostambeigi N et al. | Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. | 2011 | Transplantation | pmid:21200364 |
| Jordan ML et al. | Tacrolimus rescue therapy for renal allograft rejection--five-year experience. | 1997 | Transplantation | pmid:9020321 |
| Reich DJ et al. | Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. | 2005 | Transplantation | pmid:16003228 |
| Hardinger KL et al. | A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. | 2005 | Transplantation | pmid:16003231 |
| Ericzon BG et al. | FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. | 1992 | Transplantation | pmid:1384189 |
| Pascual J et al. | Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. | 2004 | Transplantation | pmid:15599321 |
| Peng Y et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. | 2013 | Transplantation | pmid:23263506 |
| Stephen M et al. | Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. | 1989 | Transplantation | pmid:2463701 |
| Nakazawa Y et al. | Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. | 1998 | Transplantation | pmid:9808496 |
| Meiser BM et al. | Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? | 2004 | Transplantation | pmid:15446320 |
| Griffith BP et al. | A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. | 1994 | Transplantation | pmid:7512292 |
| Jordan ML et al. | FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. | 1994 | Transplantation | pmid:7512293 |
| Sun S et al. | Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. | 1996 | Transplantation | pmid:8633368 |
| Kashu Y et al. | The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. | 1996 | Transplantation | pmid:8633382 |
| VÃtko S et al. | Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. | 2005 | Transplantation | pmid:16378069 |
| Lauzurica R et al. | Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus. | 2007 | Transplant. Proc. | pmid:17889127 |
| Miura S et al. | Long-term results of spousal renal donor transplants with donor-specific blood transfusions. | 2001 Nov-Dec | Transplant. Proc. | pmid:11750463 |
| Sato S et al. | Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. | 1998 | Transplant. Proc. | pmid:9636517 |
| Thomson AW | Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. | 1990 | Transplant. Proc. | pmid:1689883 |
| Pérez-Flores I et al. | Intracellular ATP levels in CD4+ lymphocytes are a risk marker of rejection and infection in renal graft recipients. | 2009 Jul-Aug | Transplant. Proc. | pmid:19715845 |
| Tsugita M et al. | Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. | 1994 | Transplant. Proc. | pmid:7527969 |
| Kuroki H et al. | Effect of FK 506 and donor-specific blood transfusion on the rat composite tissue limb allograft and the mechanism of long-term graft survival. | 1993 | Transplant. Proc. | pmid:7679833 |
| Machida M et al. | Effect of temperature and hematocrit on plasma concentration of FK 506. | 1991 | Transplant. Proc. | pmid:1721266 |
| Ko S et al. | Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation. | 1996 | Transplant. Proc. | pmid:8623229 |
| Braun F et al. | Primary tacrolimus immunosuppression in kidney recipients considered "higher immunologic risk". | 2000 | Transplant. Proc. | pmid:11120281 |
| Stratta RJ et al. | FK 506 induction and rescue therapy in pancreas transplant recipients. | 1996 | Transplant. Proc. | pmid:8623492 |
| Woodle ES et al. | Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. | 1999 | Transplant. Proc. | pmid:10576053 |
| O'Neill EA et al. | The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. | 1991 | Transplant. Proc. | pmid:1721298 |
| Kurnatowska I et al. | Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. | 2011 | Transplant. Proc. | pmid:21996199 |
| Iga C et al. | Prolonged survival of small intestinal allograft in the rat with cyclosporine A, FK 506, and 15-deoxyspergualin. | 1990 | Transplant. Proc. | pmid:1697118 |
| Alessiani M et al. | Total orthotopic small bowel transplantation in swine under FK 506. | 1994 | Transplant. Proc. | pmid:7518148 |
| Tada H et al. | Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. | 2005 | Transplant. Proc. | pmid:15919447 |
| Date K et al. | Effect of FK 506 on graft survival in rat small intestinal allografts. | 1992 | Transplant. Proc. | pmid:1376516 |
| Murase N et al. | Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. | 1995 | Transplant. Proc. | pmid:7533386 |
| Nakamura K et al. | Renal transplant recipient experiencing pneumatosis cystoides intestinalis: a case report. | 2003 | Transplant. Proc. | pmid:12591410 |
| Ã…berg F et al. | Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report. | 2015 | Transplant. Proc. | pmid:26680092 |
| Oike F et al. | Complete withdrawal of immunosuppression in living donor liver transplantation. | 2002 | Transplant. Proc. | pmid:12176465 |
| Moffatt SD et al. | Comparative efficacy of liposomal FK506 with FK506. | 1998 | Transplant. Proc. | pmid:9865297 |
| Malyszko J et al. | A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. | 2009 | Transplant. Proc. | pmid:19857675 |
| Ronchetti F et al. | Intestinal damage evaluation in swine allograft small bowel through hyaluronic acid quantification. | 1997 | Transplant. Proc. | pmid:9142293 |
| Scantlebury VP et al. | Outcome of kidney transplantation in African-Americans using tacrolimus. | 1997 | Transplant. Proc. | pmid:9414906 |
| Yagihashi A et al. | HLA matching effect in liver transplantation. | 1992 | Transplant. Proc. | pmid:1281569 |
| McCauley J et al. | Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. | 1991 | Transplant. Proc. | pmid:1721362 |
| Sánchez-Fructuoso AI et al. | Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors. | 2003 | Transplant. Proc. | pmid:12962759 |
| Miyazawa H et al. | Graft immunomodulation by donor irradiation and recipient-specific bone marrow cells in rat small bowel transplantation. | 2002 | Transplant. Proc. | pmid:12072357 |
| Coupes BM et al. | Tacrolimus monotherapy in renal transplantation: four-year data. | 2002 | Transplant. Proc. | pmid:12176506 |
| Renner FC et al. | Tacrolimus intoxication resolved by gastrointestinal bleeding: case report. | 2007 | Transplant. Proc. | pmid:17362773 |
| Mieles L et al. | Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1703362 |
| Cho WH et al. | Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression. | 2008 | Transplant. Proc. | pmid:18790201 |
| Scantlebury V et al. | New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. | 1991 | Transplant. Proc. | pmid:1721395 |
| Hesse CJ et al. | The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. | 2001 | Transplant. Proc. | pmid:11377487 |
| Uchida K et al. | Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. | 2002 | Transplant. Proc. | pmid:12176556 |
| Wu MS et al. | Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083527 |
| Lemahieu WP et al. | Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. | 2005 | Transplant. Proc. | pmid:15964336 |
| Tahir W et al. | Diffuse Alveolar haemorrhage: a fatal complication after alemtuzumab induction therapy in renal transplantation. | Transplant. Proc. | pmid:25645795 | |
| Langrehr JM et al. | Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. | 1991 | Transplant. Proc. | pmid:1721425 |
| Zou XM et al. | Immunosuppressive effect of FK506 on orthotopic liver and small bowel xenotransplantation (xenoOLTx and SBTx). | 1996 | Transplant. Proc. | pmid:8658729 |
| Moura Neto A et al. | Clinical Profile of Patients With Diabetes Mellitus and Liver Transplantation: Results After a Multidisciplinary Team Intervention. | 2018 | Transplant. Proc. | pmid:29661438 |
| Sundberg AK et al. | Conversion from cyclosporine to tacrolimus is preferred by pediatric renal transplant recipients: a focus on opinions and outcomes. | 2002 | Transplant. Proc. | pmid:12176640 |
| Cailhier JF et al. | CMV in kidney transplants in the tacrolimus-mycophenolate era. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267255 |
| Nalesnik MA et al. | Toxicology of FK-506 in the Lewis rat. | 1987 | Transplant. Proc. | pmid:2445084 |
| Perego C et al. | Study of the immunosuppressive effect of SMS 201-995 and its synergic action with FK 506. | 1998 | Transplant. Proc. | pmid:9723434 |
| Timmermann W et al. | Noninvasive videomicroscopic monitoring of rat small bowel rejection. | 1998 | Transplant. Proc. | pmid:9745537 |
| Laftavi MR et al. | The role of antibiotic prophylaxis in the new era of immunosuppression. | 2011 | Transplant. Proc. | pmid:21440753 |
| Chamienia A et al. | Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results. | 2014 | Transplant. Proc. | pmid:25380901 |
| Kupferman JC et al. | Activation of the renal renin-angiotensin system by cyclosporine A and FK 506 in the rat. | 1994 | Transplant. Proc. | pmid:7524224 |
| Roat MI et al. | Treatment of Cogan's syndrome with FK 506: a case report. | 1991 | Transplant. Proc. | pmid:1721457 |
| Meiser BM et al. | Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. | 1992 | Transplant. Proc. | pmid:1384201 |
| Abe T et al. | Risk factors for development of new-onset diabetes mellitus and progressive impairment of glucose metabolism after living-donor liver transplantation. | 2014 | Transplant. Proc. | pmid:24767367 |
| McCauley J et al. | Long-term lipid metabolism in combined kidney-pancreas transplant recipients under tacrolimus immunosuppression. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267475 |
| Pinho-Apezzato ML et al. | Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. | 2010 | Transplant. Proc. | pmid:20620519 |
| Umbro I et al. | Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients. | 2012 | Transplant. Proc. | pmid:22974867 |
| Starzl TE et al. | Notes on FK 506. | 1991 | Transplant. Proc. | pmid:1714647 |
| Undre NA et al. | Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients. | 1998 | Transplant. Proc. | pmid:9636451 |